+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 40Years +
All Genders
Healthy Volunteers
ID05366881

Observational Study to Validate a cfDNA Methylome Assay for Early Cancer Detection and Monitoring of Minimal Residual Disease

Led by Adela, Inc · Updated on 2026-11-04

7000

Participants Needed

17

Research Sites

47 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting an observational case-control study to evaluate a genome-wide methylome enrichment platform using cell-free DNA cfDNA to detect multiple cancer types and distinguish among them. The study focuses on common and deadly cancers, including brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid cancers. It also aims to assess the platforms ability to detect minimal residual disease and early relapse in lung cancer after treatment. Participants include individuals newly diagnosed with cancer and controls without known cancer. All participants provide a blood sample and clinical data at enrollment. Those with stage I-III lung cancer have additional blood draws and clinical follow-up after completing first-line treatment every three months for the first year, then every six months for two more years. Other cancer cases have annual clinical follow-up for three years. Controls are followed every six months for up to three years. The study uses a sensitive, bisulfite-free DNA methylation profiling assay enriched for methylated CpGs from cfDNA, followed by high-throughput sequencing. Participants provide blood samples and clinical information at baseline and during follow-up. The research team tracks cancer detection, tissue of origin, and clinical outcomes over time without sharing test results with participants or clinicians. Follow-up schedules vary by group and last up to three years or more depending on cancer type. The study measures cancer detection at 24 months and clinical outcomes at 54 months, aiming to improve early cancer detection and monitoring through this advanced liquid biopsy technology.

CONDITIONS

Brief Title

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Research Team

B

Brian Allen, MS

M

Michelle Anderson

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here